Regeneron Pharmaceuticals Inc
REGN749.790USD
+3.430+0.46%
Cierre 12/17, 16:00（ET）Cotizaciones retrasadas 15 min
78.95BCap. mercado
17.29P/E TTM
Más Datos de Regeneron Pharmaceuticals Inc Compañía
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Información de Regeneron Pharmaceuticals Inc
Símbolo de cotizaciónREGN
Nombre de la empresaRegeneron Pharmaceuticals Inc
Fecha de salida a bolsaApr 02, 1991
Director ejecutivoSchleifer (Leonard S)
Número de empleados15106
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 02
Dirección777 Old Saw Mill River Road
CiudadTARRYTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10591
Teléfono17813705000
Sitio Webhttps://www.regeneron.com/
Símbolo de cotizaciónREGN
Fecha de salida a bolsaApr 02, 1991
Director ejecutivoSchleifer (Leonard S)
Ejecutivos de Regeneron Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+10.31%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.66K
-0.10%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
15.51K
+7.93%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.62K
-0.13%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.11M
+42.02%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
670.48K
-3.59%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
56.41K
+3.71%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+2.47%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
37.73K
+5.04%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
29.89K
-0.06%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Otro
421.70M
11.47%
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Sanofi
1.44B
39.28%
EYLEA
754.30M
20.52%
Bayer
415.00M
11.29%
EYLEA HD
393.20M
10.70%
Libtayo
247.80M
6.74%
Otro
421.70M
11.47%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Otro
74.20%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
8.71%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
Otro
74.20%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
45.11%
Investment Advisor/Hedge Fund
30.91%
Hedge Fund
5.04%
Pension Fund
2.69%
Research Firm
2.61%
Bank and Trust
2.25%
Individual Investor
2.06%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
Otro
7.90%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
2023Q2
2360
99.25M
92.00%
-1.42M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
9.37M
9%
+14.55K
+0.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.67M
5.44%
-75.61K
-1.32%
Jun 30, 2025
State Street Investment Management (US)
4.83M
4.64%
+42.34K
+0.88%
Jun 30, 2025
Dodge & Cox
3.83M
3.67%
+1.50M
+64.64%
Jun 30, 2025
JP Morgan Asset Management
2.82M
2.7%
-1.26M
-30.95%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.47M
2.37%
-4.53K
-0.18%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
2.17M
2.09%
-7.70K
-0.35%
Aug 31, 2025
Putnam Investment Management, L.L.C.
2.03M
1.95%
+116.30K
+6.08%
Jun 30, 2025
Capital World Investors
1.97M
1.89%
+27.38K
+1.41%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
1.94M
1.86%
+305.09K
+18.65%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
Ver más
ProShares Ultra Nasdaq Biotechnology
Proporción6.6%
Invesco Nasdaq Biotechnology ETF
Proporción6.55%
Amplify Weight Loss Drug & Treatment ETF
Proporción6.4%
iShares Biotechnology ETF
Proporción5.9%
Simplify Health Care ETF
Proporción5.54%
VanEck Biotech ETF
Proporción5.51%
Invesco Biotechnology & Genome ETF
Proporción5.4%
iShares Genomics Immunology and Healthcare ETF
Proporción4.97%
First Trust NASDAQ Pharmaceuticals ETF
Proporción4.36%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.88%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Regeneron Pharmaceuticals Inc?
Los cinco principales accionistas de Regeneron Pharmaceuticals Inc son:
The Vanguard Group, Inc. posee 9.37M acciones, lo que representa el 9.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.67M acciones, lo que representa el 5.44% del total de acciones.
State Street Investment Management (US) posee 4.83M acciones, lo que representa el 4.64% del total de acciones.
Dodge & Cox posee 3.83M acciones, lo que representa el 3.67% del total de acciones.
JP Morgan Asset Management posee 2.82M acciones, lo que representa el 2.70% del total de acciones.
The Vanguard Group, Inc. posee 9.37M acciones, lo que representa el 9.00% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 5.67M acciones, lo que representa el 5.44% del total de acciones.
State Street Investment Management (US) posee 4.83M acciones, lo que representa el 4.64% del total de acciones.
Dodge & Cox posee 3.83M acciones, lo que representa el 3.67% del total de acciones.
JP Morgan Asset Management posee 2.82M acciones, lo que representa el 2.70% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Regeneron Pharmaceuticals Inc?
Los tres principales tipos de accionista de Regeneron Pharmaceuticals Inc son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Regeneron Pharmaceuticals Inc (REGN)?
A fecha de 2025Q3, 2596 instituciones poseen acciones de Regeneron Pharmaceuticals Inc, con un valor de mercado combinado de aproximadamente 94.26M, lo que representa el 91.26% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -4.43%.
¿Cuál es la mayor fuente de ganancias de Regeneron Pharmaceuticals Inc?
El FY2025Q2, el segmento empresarial Sanofi generó la ganancia más alta para Regeneron Pharmaceuticals Inc, ascendiendo a 1.44B y representando el 39.28% de la ganancia total.
